CC-90003
CC-90003 is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, CC-90003 inhibits ERK activity, and prevents the activation of ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is often upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival.
For research use only. We do not sell to patients.
Chemical Information
| Name | CC-90003 |
|---|---|
| Iupac Chemical Name | N-(2-((2-((2-methoxy-5-methylpyridin-4-yl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)-5-methylphenyl)acrylamide |
| Synonyms | CC-90003; CC 90003; CC90003. |
| Molecular Formula | C22H21F3N6O2 |
| Molecular Weight | 458.44 |
| Smile | C=CC(NC1=CC(C)=CC=C1NC2=NC(NC3=CC(OC)=NC=C3C)=NC=C2C(F)(F)F)=O |
| InChiKey | ILUKRINUNLAVMH-UHFFFAOYSA-N |
| InChi | InChI=1S/C22H21F3N6O2/c1-5-18(32)28-17-8-12(2)6-7-15(17)29-20-14(22(23,24)25)11-27-21(31-20)30-16-9-19(33-4)26-10-13(16)3/h5-11H,1H2,2-4H3,(H,28,32)(H2,26,27,29,30,31) |
| CAS Number | 1621999-82-3 |
| Related CAS |
Ordering Information
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid |
|---|---|
| Purity | 98% Min. |
| Storage | Dry, dark and at 0 - 4℃ for short term (days to weeks) or -20℃ for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1: Aronchik I, Dai Y, Labenski M, Barnes C, Jones T, Qiao L, Beebe L, Malek M,
Elis W, Shi T, Mavrommatis K, Bray GL, Filvaroff EH. Efficacy of a Covalent
ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms
of Response and Resistance. Mol Cancer Res. 2018 Oct 1. doi:
10.1158/1541-7786.MCR-17-0554. [Epub ahead of print] PubMed PMID: 30275173.
Chemical Structure
